account_id none on file
legal_name Concentra Group Holdings Parent, Inc.
ticker CON
cik 2014596
domain concentra.com
linkedin_company_url https://www.linkedin.com/company/concentra
entry_point_account_id none on file
name Concentra Group Holdings Parent Inc.
exchange NYSE
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 60 executives 2 family 0
why_now
growth efforts during the quarter, we added three centers in California via acquisition and one de novo center outside of Atlanta. On the de novo front, we continue to expect to open a total of eight to ten centers this year, with planne
Aug 6, 2026 / receipt
callsnone on file
filings
Completed acquisition of 3 locations in Southern California in Q1, and continue to advance pipeline of bolt-on M&A of small occupational health center practices (1-5 locations)
ir_statement / Sep 16, 2026 / receipt
Continued focus on de-levering for remainder of 2026, with net leverage ratio2 steady at 3.4x in Q1 (seasonally lowest cash flow quarter of the year). On track for <3.0x guidance by year-end.
ir_statement / Sep 16, 2026 / receipt
Opened 1 de novo in Q1 (Atlanta), targeting 8-10 total de novos in 2026
ir_statement / Sep 16, 2026 / receipt
Raising FY 2026 guidance for Revenue ($2.275bn-$2.375bn), Adjusted EBITDA1 ($460mm-$480mm), and Free Cash Flow3 ($215mm-$235mm)
ir_statement / Sep 16, 2026 / receipt
Capital Expenditures2 $11.1 $15.7 (29.5)%
ir_statement / Sep 16, 2026 / receipt
Onsite Health Clinics 411 160 +251 Largely due to Pivot Onsite Innovations acquisition in Q2 2025 (240+)
ir_statement / Sep 16, 2026 / receipt
Completed acquisition of 3 locations in Southern California in Q1, and continue to advance pipeline of bolt-on M&A of small occupational health center practices (1-5 locations)
ir_statement / Sep 16, 2026 / receipt
Continued focus on de-levering for remainder of 2026, with net leverage ratio2 steady at 3.4x in Q1 (seasonally lowest cash flow quarter of the year). On track for <3.0x guidance by year-end.
ir_statement / Sep 16, 2026 / receipt
Opened 1 de novo in Q1 (Atlanta), targeting 8-10 total de novos in 2026
ir_statement / Sep 16, 2026 / receipt
Raising FY 2026 guidance for Revenue ($2.275bn-$2.375bn), Adjusted EBITDA1 ($460mm-$480mm), and Free Cash Flow3 ($215mm-$235mm)
ir_statement / Sep 16, 2026 / receipt
Capital Expenditures2 $11.1 $15.7 (29.5)%
ir_statement / Sep 16, 2026 / receipt
Onsite Health Clinics 411 160 +251 Largely due to Pivot Onsite Innovations acquisition in Q2 2025 (240+)
ir_statement / Sep 16, 2026 / receipt
executives
| Brigid Bonner | director | - | receipt |
| Matthew DiCanio | President and Chief Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2026-08-06 | President and Chief Financial Officer, appointed | sec_8k |
| 2025-06-26 | director, appointed | sec_8k |
mcp_package_hint
slug concentra-group-holdings-parent-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$